Factbox-Companies in Alzheimer's race after US nod for Eisai/Biogen drug
Eisai Co Ltd and Biogen Inc's Leqembi emerged as the first Alzheimer's treatment to win the U.S. Food and Drug Administration's standard approval on Thursday, a milestone in drug development for a disease that has seen multiple failures in the past. The following is a list of companies that are currently developing treatments that aim to modify the memory-robbing disease: Company Drug or Stage of Mechanism Therapy development & indication Eli Lilly donanemab Designed to and Co Late-stage trial target toxic for early protein plaque Alzheimer's in the brain known as beta...